You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Apollomics has launched the Phase II portion of the Phase I/II SPARTA trial for its investigational c-MET inhibitor APL-101, which will enroll patients with different tumors and MET alterations.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments.